| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
4 companies
William A Hawkins is Director at BVS, with reported holdings spanning 4 companies. William A Hawkins's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $6.7M at current prices.
William A Hawkins's largest disclosed position is in BVS as Director, worth about $3.3M. Net of sales, the BVS filings show accumulation of 88,000 shares.
William A Hawkins has 38 Form 4 filings on record from December 2015 to June 2026, across 4 companies: Director at MiMedx Group (MDXG), 2020–2026; Director at Biogen (BIIB), 2019–2026; Director at Bioventus (BVS), 2021–2026, and 1 more.
The 43 reported transactions were 25 stock awards, 8 option exercises, 8 option or other derivative awards and 2 open-market purchases.
Counted by filing, the open-market trades come to 1 purchase worth about $236K and no sales.
The only open-market purchase was 88,000 shares of BVS at an average $2.68 on May 25, 2023, about $236K. Twelve months later BVS was up 142%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 25, 2023 | BVS Bioventus Inc. | Director | Buy | 88,000 | $2.68 | $235,567.20 | +91.4% | +50.2% | +142.2% |